featured
Fulvestrant Plus Venetoclax in ER+ Metastatic Breast Cancer Following CDK4/6 Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
VERONICA: Randomized Phase 2 Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, Biomarker Results
Clin. Cancer Res 2022 May 18;[EPub Ahead of Print], GJ Lindeman, TM Fernando, R Bowen, KJ Jerzak, X Song, T Decker, F Boyle, S McCune, A Armstrong, C Shannon, G Bertelli, CW Chang, R Desai, K Gupta, TR Wilson, A Flechais, A BardiaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.